Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Cohort Study to Determine the Long-Term Safety and Efficacy of Biogeneric Epoetin Treatment for Renal Anemia

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2005 by Ministry of Health, Malaysia.
Recruitment status was:  Active, not recruiting
Information provided by:
Ministry of Health, Malaysia Identifier:
First received: October 12, 2005
Last updated: June 12, 2008
Last verified: October 2005
The purpose of this study is to establish the long-term safety and efficacy of Biogeneric Epoetin, the attainability of therapeutic target for anaemia management, and the impact of Epoetin treatment on long-term health outcome and its cost effectiveness.

Condition Intervention Phase
Chronic Kidney Disease
End-Stage Renal Failure
Drug: Biogeneric Epoetin
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic

Resource links provided by NLM:

Further study details as provided by Ministry of Health, Malaysia:

Primary Outcome Measures:
  • To investigate the Hb levels at each every 3 months follow up visit and the incidence of lack anticipated Hb response or loss of response to Biogeneric Epoetin. To monitor the occurrence of PRCA and other immunogenicity related adverse event.

Secondary Outcome Measures:
  • Mortality, quality of life and cost during the 6 years study treatment.

Estimated Enrollment: 2000
Study Start Date: August 2005
Estimated Study Completion Date: April 2011
Detailed Description:

This study protocol is an elaboration of the original study protocol titled "A Randomized, Multi-center, Open label trial to establish the therapeutic equivalence between Biogeneric Epoetin and Eprex and to determine the long term safety profile of Biogeneric Epoetin in patients on Hemodialysis".

In the first stage, a biogeneric Epoetin shall be evaluated by a randomized trial designed to demonstrate therapeutic equivalence (TE) versus an innovator product (Eprex), the efficacy clinical end-point being Hb at 6 to 12 weeks on treatment.

When preliminary evidence of efficacy is established from above stage 1 TE trial, the product may proceed to be evaluated in a stage 2 single group cohort study designed to establish the long term safety, with particular emphasis on surveillance for occurrence of Pure Red Cell Aplasia (PRCA) and other immunogenicity related adverse event. To establish the long term efficacy, its emphasis on the potential impact of batch to batch variation in product content and potency (bioactivity) on Hb response.

This practical trial also designed to investigate the cost-effectiveness by estimating the optimal dosage for combination of Epoetin and Iron sucrose to achieve Hb target under unconstrained prescriptionas, and hence the budgetary requirement can be estimated to meet therapeutic target in this dialysis population under various pricing scenario in the presence of generic competition.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patient who has Chronic Kidney Disease with anaemia for which Epoetin treatment is indicated.
  • Patient without known hypersensitivity to the mammalian cell-derived product or human albumin products.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00238043

Pahang Buddhist Association
Kuantan, Pahang, Malaysia
Pusat Hemodialisis Islam Makmur
Kuantan, Pahang, Malaysia
SP Menon Dialysis Centre
Klang, Selangor, Malaysia
Tan Medical Renal Clinic
Petaling Jaya, Selangor, Malaysia
SP Menon Dialysis Centre
PJ, Selangor, Malaysia
Klinik Pakar Dialysis
Subang Jaya, Selangor, Malaysia
Sunway Medical Centre
Subang Jaya, Selangor, Malaysia
The Kidney Dialysis Centre
KL, Wilayah Persekutuan, Malaysia
Aiman Dialysis Centre
Kuala Lumpur, Wilayah Persekutuan, Malaysia
Ampang Putri Specialist Hospital
Kuala Lumpur, Wilayah Persekutuan, Malaysia
Cheras Dialysis Centre
Kuala Lumpur, Wilayah Persekutuan, Malaysia
Gleneagles Intan Medical Centre
Kuala Lumpur, Wilayah Persekutuan, Malaysia
Pantai Medical Centre
Kuala Lumpur, Wilayah Persekutuan, Malaysia
Smartcare Dialysis Centre
Kuala Lumpur, Wilayah Persekutuan, Malaysia
The Kidney Dialysis Centre
Kuala Lumpur, Wilayah Persekutuan, Malaysia
Sponsors and Collaborators
Ministry of Health, Malaysia
Principal Investigator: Dato' Dr. Zaki Morad Mohamad Zaher, MRCP, FRCP Department of Nephrology, Kuala Lumpur Hospital
  More Information

Additional Information: Identifier: NCT00238043     History of Changes
Other Study ID Numbers: CT 05-17
Study First Received: October 12, 2005
Last Updated: June 12, 2008

Keywords provided by Ministry of Health, Malaysia:
Biogeneric Epoetin treatment
Renal anaemia
Chronic Kidney Disease
Pure Red Blood Cell Aplasia

Additional relevant MeSH terms:
Renal Insufficiency, Chronic
Kidney Diseases
Renal Insufficiency
Kidney Failure, Chronic
Urologic Diseases
Hematologic Diseases
Epoetin Alfa
Hematinics processed this record on May 25, 2017